Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.

ABSTRACT:

Background

Trans-arterial radio-embolization (TARE) is an emerging treatment for the management of hepatocellular carcinoma (HCC). TARE may compete with systemic chemotherapy, sorafenib, in intermediate stage patients with prior chemoembolization failure or advanced patients with tumoral macrovascular invasion with no extra-hepatic spread and good liver function. We performed a budget impact analysis (BIA) evaluating the expected changes in the expenditure for the Italian Healthcare Service within scenarios of increased utilization of TARE in place of sorafenib over the next five years.

Methods

Starting from patient level data from three oncology centres in Italy, a Markov model was developed to project on a lifetime horizon survivals and costs associated to matched cohorts

SUBMITTER: Rognoni C 

PROVIDER: S-EPMC6034232 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature